| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 9, 2023 | Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A. | This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million
Jaguar currently owns approximately 73.5% of Napo Therape... |
| Jan 27, 2023 | Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, CA / ACCESSWIRE / January 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 19, 2023, the Company granted 7,500 restricted stock units (RSUs) ... |
| Jan 20, 2023 | Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st | SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Tuesday, January 31, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will p... |
| Jan 20, 2023 | Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders | All proposals approved
Company announces 1-for-75 reverse stock split to support compliance with Nasdaq listing standards
Shares of Jaguar Health common stock to begin trading on split-adjusted basis on January 23, 2023
Patient enrollment e... |
| Jan 11, 2023 | REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants | The webcast will include:
Commentary from leading breast cancer medical oncologist and hematologist Lee Schwartzberg, MD, FACP on the unmet need for a focused and biological approach to the management of cancer therapy-related diarrhea
A pr... |
| Nov 14, 2022 | Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials | Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021
Core initiatives:
OnTarget Phase 3 clinical trial of cro... |
| Sep 30, 2022 | Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders | All Proposals Approved
SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Special Meeting of Stock... |
| Aug 19, 2022 | Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule | SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on August 18, 2022 the Company received formal notice that the Listing Qualifications ... |
| Aug 5, 2022 | Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, CA / ACCESSWIRE / August 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective August 5, 2022, the Company granted 12,500 restricted stock units (RSUs) to ... |
| Jul 5, 2022 | Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions | Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee
SAN FRANCISCO, CA / ACCESSWIRE / July 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today anno... |
| Jul 1, 2022 | Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock units (RSUs) to New... |
| Jun 29, 2022 | Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China | License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months
Service agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to support approval of crofelemer in China, p... |
| Jun 22, 2022 | Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi | SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress, which took place May 19-21, 2022 in Ab... |
| Jun 21, 2022 | Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1 | Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA
SAN FRANCISCO, CA / ACCESSWI... |
| Jun 10, 2022 | Jaguar Health to Participate in BIO International Convention (BIO 2022) | Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD) and its large proprietary library of ... |
| Jun 10, 2022 | Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders | All Proposals Approved
SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Annual Meeting of Stockholder... |
| May 25, 2022 | Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition | Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea
SAN FRANCISCO, CA / ACCESSWIR... |
| May 19, 2022 | Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd! | Click here to RSVP for this in-person, outdoor event
Human and doggy swag will be available*, and the event will feature presentations by well-known veterinary cancer specialists, including Dr. Sue Cancer Vet, and performances by Broadway s... |
| May 11, 2022 | Jaguar Health Announces Launch of Mytesi Telehealth Program | This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically Appropriate for Them
SAN FRANCISCO, CA / ... |
| May 11, 2022 | TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health | SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company. The paid report was produced by TAG analyst ... |
| May 6, 2022 | Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock units (RSUs) to Mark J... |
| May 5, 2022 | Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates | Click here to register for webcast
Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022
SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced ... |
| May 5, 2022 | UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates | Click here to register for webcast
Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022
SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced ... |
| Apr 15, 2022 | Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"... |
| Nov 19, 2021 | Jaguar Health : Reports 2021 Third Quarter Financial Results - Form 8-K | Jaguar Health Reports 2021 Third Quarter Financial Results
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021
Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million
Compa... |
| Nov 19, 2021 | Jaguar Health : Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients | Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication
SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Ph... |
| Nov 1, 2021 | Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(4) | SAN FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced that, effective October 25, 2021, the Company granted nonstatutory stock options for the purchase of up to 2,666 shares of the Company's common stoc... |
| Sep 24, 2021 | Jaguar Health : Receives 'Complete' Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in DogsSAN | FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) announced that it was informed on September 21, 2021 by the FDA's Center for Veterinary Medicine (CVM) that the Target Animal Safety (TAS) technical section of the company's application for ... |
| Sep 6, 2021 | Jaguar Health : Announces 1-for-3 Reverse Stock Split | SAN FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ('Common Stock'), at an exchange ratio of 1-for... |
| Aug 9, 2021 | Jaguar Health : Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote | SAN FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the 'Annual Meeting') for a fourth time due to a lack of quorum. The ... |
| Aug 6, 2021 | Jaguar Health : Jaguar Health, Inc. | Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 &am... |
| Jul 26, 2021 | Jaguar Health : Jaguar Health, Inc. | Jaguar Health Announces that Innovators with Jane King Interview with
Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
Registration link for webcast appears below
S... |
| Jul 16, 2021 | Jaguar Health : Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote (Form 8-K) | Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 74% have voted in favor of Proposals 2, 3, 4 & ... |
| Jun 14, 2021 | JAGUAR HEALTH, INC.
Jaguar Health : Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote | SAN FRANSICO, CA - Jaguar Health, Inc. (Nasdaq:JAGX) ('Jaguar' or the 'Company') announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the 'Annual Meeting') for a second time due to a lack of quorum. The a... |
| Jun 11, 2021 | JAGUAR HEALTH, INC.
Jaguar Health : Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 (Form 8-K) | Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6
Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum
San Francisco, CA (June 11, ... |
| Jun 7, 2021 | JAGUAR HEALTH, INC.
Jaguar Health : Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(4) | SAN FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced that effective May 27, 2021, the Company granted nonstatutory stock options for the purchase of up to 225,000 shares of the Company's common stock t... |
| May 1, 2021 | JAGUAR HEALTH, INC.
Jaguar Health : Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan | Jaguar Health Announces $10.8 Million Registered Direct
Offering for the Benefit of Napo EU Business Plan
Company terminates at-the-market (ATM) financing program
San Francisco, CA (April 29, 2021): Jaguar Health, Inc. (NASDAQ:JAGX) ('Jagua... |
| Apr 5, 2021 | JAGUAR HEALTH, INC.
Jaguar Health : Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(4) | SAN FRANCISCO, CA. - Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective March 26, 2021, the Company granted nonstatutory stock options for the purchase of up to 2,000 shares of the Company's common ... |
